Efficacy and tolerability of losartan in patients with essential hypertension: A multicentre, double-blind comparison of losartan with metoprolol

Journal of Clinical and Basic Cardiology

Volumn 8, Issue 1-4, 2005, Pages 43-46

  Dobovisek J ^a   Spinar J ^b   Niegowska, J ^c   Soucek M ^b   Kanic V ^d   Rekic S ^e  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^c INSTITUTE OF CARDIOLOGY   (Poland)

^d UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

^e KRKA D D   (Slovenia)

Author keywords

Essential hypertension; Losartan; Metoprolol

Indexed keywords

LOSARTAN; METOPROLOL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; EVALUATION; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; VERTIGO;

EID: 31744434115     PISSN: 15612775     EISSN: 16809386     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Kjeldsen SE, Julius S, Hedner T, Hansson L. Stroke is more common than myocardial infarction in hypertension: analysis based on 11 major randomized intervention trials. Blood Press 2001; 10: 190-2.
2. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998; 317: 703-13.
3. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990; 335: 827-38.
4. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, Bulpitt CJ, De Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A, for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 35: 757-64.
5. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S, for the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.
6. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, De Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE, for the CAPPP Study Group. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP). Lancet 1999; 353: 611-6.
7. Hansson L. Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, Wester PO, Hedner T, de Faire U, for the STOP-2 Hypertension Study Group. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity. The Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-6.
8. The HOPE Study Investigators. Effects of an angiotensin-converting enzyme inhibitor ramipril on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.
9. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, De Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
10. Pitt B, Poole-Wilson P, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - The Losartan Heart Failure Survival Trial ELITE II. Lancet 2000; 355: 1582-7.
11. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
12. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-75.
13. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, for the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.
14. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, for the Irbesartan in Patients with Type II Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-8.
15. Goldberg AI, Dunlay M, Sweet SC. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995; 75: 793-5.
16. Dahlöf B, Keller SE, Makris L, Goldberg AI, Sweet CS, Lim NY. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens 1995; 8: 578-83.
17. Farsang C, Garcia-Puig J, Niegowska J, Baiz AQ, Vrijens F, Bortman G, for the Losartan ISH Investigators Group. The efficacy and tolerability of losartan versus atenolol in patients with isolated systolic hypertension. J Hypertens 2000; 18: 795-801.
18. Pouleur HG. Clinical overview of irbesartan: a new angiotensin II receptor antagonist. Am J Hypertens 1997; 10: 318-24S.
19. Stumpe KO, Haworth D, Hoglund C, Kerwin L, Martin A, Simon T, Masson C, Kassler-Taub K, Osbakken M. Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension. Blood Press 1998; 7: 31-7.
20. Guidelines Subcommittee. 1999 World Health Organization - International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151-83.
21. Willenheimer R, Dahlöf B, Rydberg E, Erhardt E. AT-1 receptor blockers in hypertension and heart failure: clinical experience and future directions. Eur Heart J 1999; 20: 997-1008.
22. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2002; 25: 213-29.
23. Johnston IC. Angiotensin receptor antagonists: focus on losartan. Lancet 1995; 346: 1403-7.
24. Krichbaum D, Abramowitz B. Focus on losartan: an angiotensin II receptor antagonist for treatment of hypertension. Hosp Form 1994; 29: 683-96.
25. Vitovec J, Špinar J. Hypertension and combination drug therapy. Cor Vasa 2000; 42: 461-7.
26. Accetto R, Dobovišek J. Slovene guidelines for the management of patients with arterial hypertension. Ljubljana: Slovene Society for Hypertension 2000: 1-66.
27. Laakso M, Karjalainen L, Lempiainen-Kuosa P. Effects of losartan on insulin sensitivity in hypertensive subjects. Hypertension 1996; 28: 392-6.
28. Malmquist K, Kahan T, Edner M, Held C, Hagg A, Lind L, Muller-Brunotte R, Nystrom F, Ohman KP, Osbakken MD, Ostergern J. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001; 19: 1167-76.